Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-00345439 · 2 trials · 2 indications
Drug liking assesses the degree that a participant likes a drug effect at the time the question is being asked (that is, at the moment). It is scored using a 100 mm unipolar visual analogue scale (VAS); where 0 mm = Not at all and 100 mm = Extremely.
High assesses the degree that a subject feels a good effect (ie euphoria) at the time the question is being asked (that is, at the moment). It is scored using a 100 mm unipolar scale); where 0 mm = Not at all and 100 mm = Extremely.
Drug liking assesses the degree that a participant likes a drug effect at the time the question is being asked (that is, at the moment). It is scored using a 100 mm unipolar visual analogue scale (VAS); where 0 mm = Not at all and 100 mm = Extremely.
High assesses the degree that a subject feels a good effect (ie euphoria) at the time the question is being asked (that is, at the moment). It is scored using a 100 mm unipolar scale); where 0 mm = Not at all and 100 mm = Extremely.
| Arm | Type | Description |
|---|---|---|
| PF-00345439 (oxycodone) | EXPERIMENTAL | PF-00345439 (oxycodone) |
| Treatment A | PLACEBO_COMPARATOR | Placebo solution +placebo capsule + placebo capsule chewed. |
| Treatment B | EXPERIMENTAL | PF-00345439 taken whole + placebo solution + placebo chewed |
| Treatment C | EXPERIMENTAL | PF-00345439 chewed + placebo solution + placebo taken whole |
| Treatment D | ACTIVE_COMPARATOR | Oxycodone HCl immediate-release 40 mg tablets (eg, 2 x 5 mg + 1 x 30 mg) + placebo taken whole + placebo chewed |
| Name | Type | Description |
|---|---|---|
| PF-00345439 | DRUG | 5-80 mg twice-a-day for 12 months |
| Capsule | DRUG | Taken once |
| oxycodone | DRUG | 40 mg solution, taken once |
Inclusion Criteria: * Males and females who are ≥ 18 and ≤ 75 years of age with moderate to severe pain in one or more hip or knee joint(s) caused by osteoarthritis for at least three months prior to the Baseline Visit or persistent moderate to severe low back pain for at least six months while reg...
PF-00345439 is a small molecule being developed for pain management. It has been studied in clinical trials for pain and in opioid users. The drug is currently in Phase 1 development and is being developed by Cassava Sciences, Inc.
PF-00345439 is being developed by Cassava Sciences, Inc., a biopharmaceutical company. The company is conducting clinical trials to evaluate the drug's safety and efficacy for pain-related conditions.
PF-00345439 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials have been completed to assess its safety and potential effects.
PF-00345439 has been studied in two completed clinical trials. One trial (NCT01559701) evaluated long-term safety in 823 participants with pain. Another trial (NCT01986283) assessed abuse potential in 67 opioid users. Both trials were randomized, double-blind, and placebo-controlled.
PF-00345439 is not the same as oxycodone. A clinical trial titled "Long-term Safety of PF-00345439 (Oxycodone)" suggests the drug may be related to or compared with oxycodone, but PF-00345439 is a distinct investigational compound being developed by Cassava Sciences.